Breaking News, Collaborations & Alliances

Edison, Dainippon Sumitomo in R&D Alliance

Receives $35 mil. upfront for orphan treatments

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Edison Pharmaceuticals has entered into a research, development and commercialization agreement with Dainippon Sumitomo Pharma (DSP) for the development of EPI-743 and EPI-589 in Japan.   Edison will receive $35 million upfront and $15 million in R&D support, and will be eligible to receive as much as $35 million in development milestones, and as much as $460 million in royalties on sales. DSP will gain development and commercialization rights in Japan.   DSP will be responsible for developm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters